Amgen To Acquire Privately-Held Dezima Pharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Leerink Partners Remains Bullish on Xencor, Inc. (XNCR) Following Announced Amgen Inc. (AMGN) Collaboration
September 16, 2015 10:10 AM EDTLeerink Partners reiterated an Outperform rating and $25.00 price target on Xencor, Inc. (NASDAQ: XNCR) following an announced collaboration with Amgen Inc. (NASDAQ: AMGN). The collaboration will combine AMGN's proprietary antibodies and XNCR's bispecific platform to develop new therapeutic candidates for cancer... More
Amgen (AMGN) to Acquire Dezima Pharma in $1.55B Deal
September 16, 2015 9:05 AM EDTAmgen (NASDAQ: AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.
"With the recent launches of Repatha (evolocumab) and Corlanor® (ivabradine), and today's acquisition of Dezima, Amgen is proud to be on the leading edge of an exciting new wave of treatments for cardiovascular disease, an illness impacting millions of people worldwide," said Robert A. Bradway, chairman and chief... More
